Eli Lilly Stock: Buy the Dip with a Low-Cost Vanguard ETF

Eli Lilly (LLY) is down 15.6% YTD due to its high dependence on weight loss drugs, which accounted for 56% of total revenue in 2025. Despite a lofty P/E ratio of 40.1, the company's breakthrough growth rate could make it look cheap in hindsight. The Vanguard Healthcare ETF (VHT) is a low-cost option with a 12.6% weighting in Lilly and diversified exposure to the healthcare sector, making it a better buy than LLY.